Prognostic significance of p53 mutations in non-small cell lung cancer: A meta-analysis of 829 cases from eight published studies

Cancer Letters

Volumn 153, Issue 1-2, 2000, Pages 219-226

  Huncharek, Michael ^a,b   Kupelnick, Bruce ^b   Geschwind, J F ^c   Caubet, J F ^d  

^a MARSHFIELD CLINIC   (United States)

^b Meta Analysis Research Group   (United States)

^c JOHNS HOPKINS HOSPITAL   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Clinical epidemiology; Meta analysis; Prognosis; Survival

Indexed keywords

PROTEIN P53;

ARTICLE; CANCER SURVIVAL; CLINICAL TRIAL; DNA SEQUENCE; GENE MUTATION; GENETIC HETEROGENEITY; HISTOLOGY; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; META ANALYSIS; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; SINGLE STRAND CONFORMATION POLYMORPHISM; TUMOR SUPPRESSOR GENE;

CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS; HUMANS; LUNG NEOPLASMS; MUTATION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0034729357     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(00)00381-5     Document Type: Article

References (23)

1. Miller B.A., Ries L.A.G., Handley H., et al. SEER Cancer Statistics Review: 1973-1990. 1993, National Cancer Institute. NIH No. 93-2789.
2. Ihde D.C., Minna J.D. Non-small Lung Cancer. Part II. Treatment. Haskell C.M. Current Problems in Cancer. 1991;107-154 Mosby Year Book, St. Louis, MO.
3. Greenblatt M.S., Bennett W.P., Hollstein M., Harris C.C. Mutations in the p53 tumor suppressor gene; clues to cancer etiology and molecular pathogenesis. Cancer Res. 54:1994;4855-4878.
4. Kastan M.B., Onyekwere O., Sidransky D., Vogelstein B., Craig R.W. Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 51:1991;6304-6311.
5. Quinlan D.C., Davidson A.G., Summers C.L., Warden H.E., Dashi H.M. Accumulation of p53 protein correlates with a poor prognosis in human lung cancer. Cancer Res. 52:1992;4828-4831.
6. Cooper H., Hedges L.V. The Handbook of Research Synthesis. 1994;Russell Sage Foundation, New York.
7. Greenland S. Quantitative methods in the review of epidemiologic literature. Epidemiol. Rev. 9:1986;1-30.
8. Mitsudomi T., Oyama T., Kusano T., Ojaki T., Nararishi R., Shirakusa T. Mutations of the p53 gene as a predictor of poor prognosis in patients with non-small cell lung cancer. J. Natl. Cancer Inst. 85:(24):1993;2018-2023.
9. Horio Y., Takahashi T., Kurioshi T., Hibi K., Suyama M., Niinu T., Shimokata K., Yamakawa K., Nakamura Y., Ueda R., Takahashi T. Prognostic significance of p53 mutations and 3p deletions in primary resected non-small cell lung cancer. Cancer Res. 53:1993;1-4.
10. Fukuyama Y., Mitsudomi T., Sugio K., Ishida T., Akazawa K., Sugimachi K. k-ras and p53 mutations are an independent unfavorable prognostic indicator in patients with non-small cell lung cancer. Br. J. Cancer. 75:(8):1997;1125-1130.
11. Top B., Mooi W.J., Klaver S.G., Boerrigter L., Wisman P., Elbers H.R.J., Visser S., Rodenhui S. Comarative analysis of p53 gene mutations and protein accumulation in human non-small cell lung cancer. Int. J. Cancer. 64:1995;83-91.
12. Carbone D.P., Mitsudomi T., Chiba I., Piantadosi S., Rusch V., Nowak J.A., McIntire D., Slamon D., Gazdar A., Minna J. p53 immunostaining positivity is associated with reduced survival and is imperfectly correlated with gene mutation in resected non-small cell lung cancer. Chest. 106:(6):1994;377S-381S.
13. Vega F.J., Iniesta P., Caldes T., Sanchez A., Lopez J.A., deJuan C., Diaz-Rubio E., Torres A., Balibrea J.L., Benito M. p53 exon 5 mutations as a prognostic indicator or shortened survival in non-small cell lung cancer. Br. J. Cancer. 76:(1):1997;44-51.
14. Maria de Anta J., Jassem E., Rossell R., Marinez M., Jassem J., Martinez-Lopez E. TP53 mutational pattern in Spanish and Polish non-small cell lung cancer patients: Null mutations are associated with poor prognosis. Oncogene. 15:(24):1997;2951-2958.
15. Guang S.G., Ogura T., Sekine I., Yakozaki M., Esmui H., Kodama T., Nagai K. Association between p53 mutation and clinicopathological features of non-small cell lung cancer. Jpn. J. Clin. Oncol. 27:(4):1997;211-215.
16. Mitsudomi T., Oyama T., Nishida K., Ogami A., Osuri T., Naronishi R., Sugio K., Yasmato K., Sugmachi K. p53 nuclear immunostaining and gene mutations in non-small cell lung cancer and their effect on patient survival. Ann. Oncol. 6:(Suppl. 3):1995;S9-S13.
17. Visscher D.W., Yandrandj S., Tabaczka P., Kraut M., Sarkar F.H. Clinicopathologic analysis of k-ras, p53 and ERBB-2 gene alterations in pulmonary adenocarcinoma. Diagn. Mol. Pathol. 6:(1):1997;64-69.
18. Ludwig R.L., Bates S., Vouiden K.H. Differential activation of target cellular promoters by p53 mutants with impaired apoptotic function. Mol. Cell. Biol. 16:1996;4952-4960.
19. Ko I.J., Prives C. p53: puzzle and paradigm. Genes Dev. 10:1996;1054-1072.
20. Pocard M., Chevillard S., Villaudy J., Paupon M.F., Dutoillaux B., Remvikos Y. Different p53 mutations produce distinct effects on the ability of colon carcinoma cells to become blocked at the G1/S boundary after irradiation. Oncogene. 12:1996;875-882.
21. Anderson T.I., Holm R., Nesland J.M., Heimdal K.R., Uttestal L., Borresen A.L. Prognostic significance of TP53 alterations in breast carcinoma. Br. J. Cancer. 68:1993;540-548.
22. Iwamoto K.S., Mizuno T., Ito T., Tsuyuma N., Kyoizumi S., Seyama T. Gain of function mutations enhance alteration of the T-cell receptor following X-irradiation independently of the cell cycle and cell survival. Cancer Res. 56:1996;3862-3865.
23. Asa T., Borresen A.L., Geiser S., Smith-Sorensen B., Johneon H., Varbay J.E., Akshen L.A., Lonning P.E. Specific p53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat. Med. 2:1996;811-814.